A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870

Completed

Phase of Trial:
Phase III

Latest Information Update:12 Nov 2017

At a glance

Drugs
Certolizumab pegol (Primary)

Indications
Crohn's disease

Focus
Registrational; Therapeutic Use

Acronyms
PRECiSE-2

Sponsors
UCB

Most Recent Events

12 Nov 2017
Outcomes of a population pharmacokinetic model assessing exposure-response relationship of of certolizumab pegol using pooled data from nine clinical trials of certolizumab pegol induction and maintenance therapy in patients with Crohns disease, including C87005,C87031,C87032, C87037, C87042, C87043,C87047, C87048 and C87085, published in the Alimentary Pharmacology and Therapeutics Journal.

10 Jun 2017
Biomarkers information updated

02 Nov 2011
Additional results from PRECiSE 2 were presented at the 76th Annual Scientific Meeting of the American College of Gastroenterology.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login
with a username/password associated to an account with a valid subscription